Share on StockTwits

Investment analysts at Societe Generale lifted their price target on shares of Bioamber (NASDAQ:BIOA) to $16.00 in a note issued to investors on Friday. Societe Generale’s target price would suggest a potential upside of 34.79% from the company’s current price.

Bioamber (NASDAQ:BIOA) traded up 1.35% during mid-day trading on Friday, hitting $12.0299. The stock had a trading volume of 59,211 shares. Bioamber has a one year low of $3.96 and a one year high of $15.29. The stock has a 50-day moving average of $10.65 and a 200-day moving average of $11.11. The company’s market cap is $223.3 million.

Bioamber (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.01. Analysts expect that Bioamber will post $-1.85 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Barclays cut their price target on shares of Bioamber from $22.00 to $20.00 in a research note on Thursday.

In other Bioamber news, EVP Michael A. Hartmann acquired 3,000 shares of the stock in a transaction dated Wednesday, July 16th. The stock was purchased at an average price of $12.00 per share, with a total value of $36,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BioAmber Inc (NASDAQ:BIOA) is a chemical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.